Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.70001 ↗At a glance
Journal article in Pharmacology Research & Perspectives, 2024. Written by Daichi Yamaguchi and 2 co-authors. Institution: Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan. Major MEDLINE topics: Cephalosporins, Anti-Bacterial Agents, Cefiderocol. Cited 1 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Shionogi.
Abstract (original language)
When planning pediatric clinical trials, optimizing the sample size of neonates/infants is essential because it is difficult to enroll these subjects. In this simulation study, we evaluated the sample size of neonates/infants using a model‐based optimal approach for identifying their pharmacokinetics for cefiderocol. We assessed the usefulness of data for estimation performance (accuracy and variance of parameter estimation) from adults and the impact of data from very young subjects, including preterm neonates. Stochastic simulation and estimation were utilized to assess the impact of sample size allocation for age categories in estimation performance for population pharmacokinetic parameters in pediatrics. The inclusion of adult pharmacokinetic information improved the estimation performance of population pharmacokinetic parameters as the coefficient of variation (CV) range of parameter estimation decreased from 4.9%–593.7% to 2.3%–17.3%. When sample size allocation was based on the age groups of gestational age and postnatal age, the data showed 15 neonates/infants would be necessary to appropriately estimate pediatric pharmacokinetic parameters (
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan.
- Pharmacokinetics/Pharmacodynamics & Pharmacometrics, Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K, Kobe, Japan.
ORCID profiles: Daichi Yamaguchi
Funding
- Shionogi
Cite
APA
Yamaguchi, D., Katsube, T., & Wajima, T. (2024). Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70001
Vancouver
Yamaguchi D, Katsube T, Wajima T. Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.70001
BibTeX
@article{Yamaguchi2024,
author = {Yamaguchi, Daichi and Katsube, Takayuki and Wajima, Toshihiro},
title = {Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.70001}
}
EUVIMED